This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Swords, F. M. Articles by Monson, J. P. Search for Related Content PubMed PubMed Citation Articles by Swords, F. M. Articles by Monson, J. P. Pubmed/NCBI databases Substance via MeSH

Stereotactic Radiosurgery XVI: A Treatment for Previously Irradiated Pituitary Adenomas

Departments of Endocrinology (F.M.S., C.A.A., S.L.C., A.B.G., G.M.B., J.P.M.), Radiotherapy (P.N.P., A.S.), and Radiology (J.E.), St. Bartholomew’s and The Royal London School of Medicine, London EC1A 7BE, United Kingdom

Address all correspondence and requests for reprints to: Professor J. P. Monson, M.D., F.R.C.P., Department of Endocrinology, St. Bartholomew’s and The Royal London School of Medicine, Queen Mary University of London, West Smithfield, London EC1A 7BE, United Kingdom. E-mail: j.p.monson{at}qmul.ac.uk.

We report the use of stereotactic radiosurgery delivered through an adapted linear accelerator [stereotactic multiple arc radiation therapy (SMART)] for pituitary adenomas not cured by conventional therapy. All 21 patients had undergone conventional radiotherapy (45–50 Gy); 18 had also undergone prior surgery. This cohort comprised 13 patients with somatotrope adenomas, four with corticotrope adenomas, one with a lactotrope adenoma, and three with nonfunctioning pituitary adenomas (median follow-up: 33 months, range: 3–72 months).

SMART has proven effective, safe, and rapidly acting. We observed an accelerated reduction in GH and IGF-I levels in acromegaly, with normalization of GH and IGF-I levels in 58%. Mean GH fell from 21.1 mU/liter to 7.9 mU/liter (7 ng/ml to 2.6 ng/ml, P < 0.01, median 25 months) faster than our predicted fall to 50% at 2 yr with conventional radiotherapy. Mean IGF-I fell from 624 ng/ml to 384 ng/ml (P < 0.001). Tumor growth was controlled in two of three nonfunctioning pituitary adenomas, and three of four corticotrope adenomas.

There were no adverse effects from SMART. Notably there have been no visual sequelae or further loss of anterior pituitary function in this heavily pretreated group. Our data indicate that SMART is an effective complementary therapy for pituitary adenomas that have displayed a suboptimal response to conventional therapy including external irradiation.

Abbreviations: Linac, Conventional linear accelerator; MRI, magnetic resonance imaging; PRL, prolactin; SMART, stereotactic multiple arc radiation therapy.

This article has been cited by other articles:

				G. A. Kaltsas, P. Nomikos, G. Kontogeorgos, M. Buchfelder, and A. B. Grossman Diagnosis and Management of Pituitary Carcinomas J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 3089 - 3099. [Abstract] [Full Text] [PDF]

				A K El Hamri, J Monk, and P N Plowman Stereotactic radiosurgery at St. Bartholomew's hospital: third quinquennial review Br. J. Radiol., May 1, 2005; 78(929): 384 - 393. [Full Text] [PDF]